Sun, Chaoyang
Li, Xi
Guo, Ensong
Li, Na
Zhou, Bo
Lu, Hao
Huang, Jia
Xia, Meng
Shan, Wanying
Wang, Beibei
Li, Kezhen
Weng, Danhui
Xu, Xiaoyan
Gao, Qinglei
Wang, Shixuan
Hu, Junbo
Lu, Yiling
Mills, Gordon B.
Chen, Gang
Article History
Received: 25 January 2019
Revised: 21 October 2019
Accepted: 28 October 2019
First Online: 8 November 2019
Compliance with ethical standards
:
: GBM is a SAB member or Consultant with AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMET, Ionis, Signalchem Lifesciences, Symphogen, Takeda/Millennium Pharmaceuticals, and Tarveda, has Stock Options or Financial arrangements with Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindle Top Ventures, Tarveda, has Licensed Technology with a HRD assay to Myriad Genetics and a DSP patent with Nanostring and has sponsored Research with Adelson Medical Research Foundation, AstraZeneca, Breast Cancer Research Foundation, Immunomet, Ionis, Komen Research Foundation, Nanostring, Ovarian Cancer Research Foundation, Pfizer, Prospect Creek Foundation, and Takeda/Millennium Pharmaceuticals. The authors declare that they have no conflict of interest.